
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at its N-terminus to extend its plasma half-life versus native GHRH.
Binds to the GHRH receptor on anterior pituitary somatotrophs, stimulating pulsatile endogenous growth hormone release. Research literature describes downstream effects on IGF-1 and lipolysis in adipose tissue.
FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy in 2010. Continues to appear in metabolic and body-composition research.
Published research literature covers the following areas:
LAR supplies this compound as a reference standard to qualified laboratories. No dosing schedules, administration methods, or human-use guidance is provided or implied.
Sealed vial: Stable at refrigerated temperatures (2–8 °C) for up to 24 months. Stable at room temperature (up to 25 °C) for 30 days during shipping.
After opening: Refrigerate at 2–8 °C and use within 30 days. Protect from light. Do not freeze after opening.
Visual check: Solution should remain clear. Discard if discoloration or precipitate appears.
Every batch is independently tested for purity, mass, and endotoxin load. Click any report to view the full analysis.
No. Research peptides supplied by LAR are reference materials for laboratory investigation. They are not approved by the FDA or any national regulatory body for human use.
Yes. Vials ship as lyophilized powder, giving your lab control over solvent selection and final concentration. Reconstitution should follow your laboratory's standard practice.
Each manufacturing batch is tested by an independent third-party laboratory using HPLC-UV analysis. The full report, including chromatogram and mass spectrometry, is available above.
Orders ship within 1–2 business days via discreet packaging.